ABBV: AbbVie Beats Street on Soaring Humira Sales

Global sales also topped analysts' estimates

   

ABBV: AbbVie Beats Street on Soaring Humira Sales

On Friday, AbbVie (ABBV) reported higher quarterly earnings and revenues. ABBV stock rose more than 3% in morning trading.

abbvie ABBV: AbbVie Beats Street on Soaring Humira SalesABBV shares moved higher after the pharmaceutical-maker said it earned $980 million during the first quarter, up 1.2% from $968 million in the prior-year period. Adjusted EPS came in at 71 cents, beating guidance issued earlier this year, Reuters noted.

Day Trading 1851 ABBV: AbbVie Beats Street on Soaring Humira Sales
Biggest Movers in Healthcare Stocks Now – VOLC PBYI ABBV

Quarterly sales climbed to $4.56 billion, up 5.4% over the year-ago period, and topping the $4.33 billion that Wall Street was expecting.

AbbVie said that its first quarter results were boosted by a 18% jump in worldwide sales of its rheumatoid arthritis drug, Humira, the Wall Street Journal noted. During the quarter, global Humira sales hit $2.6 billion.

On Thursday, AbbVie stock closed at $49.32 per share.

More Stocks in the News:


Article printed from InvestorPlace Media, http://investorplace.com/2014/04/abbv-abbvie-beats-street-soaring-humira-sales/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.